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ABSTRACT
Plaque assays that can detect single antibody-forming cells can be highly
informative. A need was identified for a plaque assay which uses nucleated
cells as targets, instead of the traditional erythrocyte targets. The objective of
this thesis was to develop such an assay and to try it on some simple cellular
problems in the field of monoclonal antibody technology.
The principle of the plaque assay was to use carboxyfluorescein diacetate
to stain living, EBV-transformed target cells and a red fluorescent dye [propi-
dium iodide) to stain the dead cells, in a plaque, that had been lysed by anti-
body and complement. A fluorescence microscope was then used to count the
plaques. The final method involved the use of microscope slides for the assay
and resulted in permanent preparations that could be stored and examined at
leisure.
Trials with this technique using a mouse hybridoma, Nfld.M2, secreting
cytotoxic antibody of anti-HLA-A2 and A28 specificity and of IgG2a subclass
showed that less than 22% of these recently cloned cells formed plaques and
that the majority of the cells were not secreting antibody, at least at levels
detectable in this plaque assay. Efforts to increase the number of plaques by
the use of a second antibody revealed a prozone effect. Another mouse hybri-
doma , Nfld.Ml, secreting non-cytotoxic antibody of anti-DR4 specificity and of
IgGl subclass was also used in the plaque assay. No plaques were obtained
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even with the addition of developing antiserum.
A human hybridoma, NOd.HI, secreting cytotoxic antibody of IgM class
was also used in the plaque assay. No plaques were observed and this was
attributed to the low rate of antibody secretion by the hybridoma cells. When
human EBV-transformed cells were used in the plaque assay as a source of
antibody-secreting cells, clear and distinct plaques were obtained.
The experiments described here show that the plaque assay is suitable for
use in analysing problems in cellular immunology in both mouse and human
systems. The results have revealed at least one unexpected finding and this is
the low proportion of antibody secreting cells found in a clone and ways are
suggested for further research on these. Finally, the method for producing per-
manent preparations for immunoOuorescence may find other applications for
teaching or research.
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CHAPTER 1
INTRODUCTION AND OBJECTIVES
A method capable of detecting individual cells secreting anti-Hl.A anti-
body is described in this thesis. Single cell methods for detecting antibody-
forming cells have been in existence for many years and have been developed
and modified to aid in counting and identifying cells forming and secreting
antibody; however, with few exceptions, they either involved red cells as tar-
gets or else were delicate and demanding techniques, involving the use of
micromanipulation. The aim of this study was to develop a method where
nucleated cells are used as targets. In this chapter, some of the earlier pub-
lished methods and their uses will be reviewed .
1.1. Immunofluorescent and Microdroplet techniques
Most of the earlier single cell methods were developed and used for the
purpose of identifying antibody-forming/secreting cells. Reiss, Mertens and
Ehrich (Hl50) demonstrated antibody-forming cells in the lymph nodes of
immunized rabbits by the method of bacterial adherence. Cell suspensions
made from these lymph nodes were incubated along with the bacteria of the
immunizing strain on a slide and observed microscopically. They noted that
certain lymphoid cells from these lymph nodes agglutinated on their surface
the bacteria of the immunizing strain. They identified these antigen-binding
cells as being members of the plasma cell series, thus confirming the observa-
tions of Fagraeus (IQ48) who was one of the first investigators to suggest , from
morphological observations, that antibody-forming cells belonged to th e
plasma cell series. She had examined spleens from immunized animal s and
had found that cells identified as plasmablasts began to appear 2 or 3 days
after antigen administration.
Coons , Leduc and Connolly (1955) examined various organs and tissues
from hyperimmune rabbits for antibody-containing cells using the fluorescent
antibody technique. This technique had been developed by Coons , Creech ,
Jones and Berliner in 1942. They showed that fluorochromes could be conju-
gated to antibody without altering the ability of the antibody to combine with
antigen. To demonstrate the presence of antibody in various organs and tis-
sues from immunized animals, they incubated frozen sections of these tissues
with the appropriate antigen followed by the conjugated antibody to the sam e
antigen . Antibody-containing cells fluoresced when viewed under a fluores-
cence microscope. They demonstrated these antibody-containing cells in the
red pulp of the spleen, the medullary areas of the lymph nodes, the submucosa
of the ileum and the portal connective tissue of the liver. These antibody-
containing cells were identified as plasma cells.
Nossal and Lederberg (1958) described a single cell technique in which
antibody production by single cells isolated in microdroplets could be det ected .
In this technique, popliteal lymph nodes from rat s immunized with Salmonella
flagellar antigen were removed and processed to give a cell suspension . Single
cells were isolated in microdroplets (volume: 10-7_ 10-6 ml) on the surface of a
coverslip and then immersed in paraffin oil. The coverslip was then inverted
over a chamber filled with oil and incubated at 37 0 C for a few hours. The
chambers were next placed on the stage of a microscope. With the aid of a
micropipette, bacteria of the immunizing strain were instilled into each micro-
droplet. The presence of anti-flagellar antibody was detected by specific
immobilization of these bacteria.
Using this technique, Nossal and Lederberg demonstrated the validity of
the one-cell-one-antibody theory. They immunized rats with two antigens and
found that"single cells made antibody to one or the other antigen but not to
both . Nossal (lgSgb) showed that the difference between primary and secon-
dary responses was due to the fact that the proportion of cells actively secret-
ing antibody was far higher in the secondary response. This was also shown
by Leduc, Coons and Connolly (lgSS) by the fluorescent antibody technique.
Nossal (lgSg) also confirmed that most of the antibody-producing cells resem-
bled plasma cells.
The work of Nossal was further improved by using bacterial adherence to
preselect antibody-forming cells from among a mixed population of antibody-
forming and non-antibody-forming cells; these marked cells could then be
removed with a micropipette for use in detailed single cell studies [Makela and
Nossal, Ig61). Nossal, Szenberg, Ada and Austin (lg64), using this technique,
demonstrated the phenomenon of isotype switching. They showed the sequen-
tial appearance of IgM and IgG antibody for the primary and secondary
responses, respectively. Cell suspensions were made from lymph nodes after
primary and secondary immunizations (the secondary immunization was 6-8
weeks after the primary) in rats. Bacterial adherence positive cells were iso-
lated individually in microdroplets and incubated as usual. Following the
incubation, a small sample of each drop was removed, diluted and then divided
into four equal parts. Droplets in the first group were treated with mercap-
toethanol while droplets in the second group were treated with anti-7S globulin
serum. Those in the third group were treated sequentially with both. The
fourth group of droplets was left undisturbed. The untreated and doubly
treated microdroplets served as positive and negative controls, respectively.
Bacteria were then added to each droplet. The cells in the droplets that had
been treated with mercaptoethanol and could not immobilize the bacteria were
classified as IgM producers. The cells in the droplets that had been treated
with the anti-7S serum and had lost their immobilizing activity but were
unaffected by mercaptoethanol were classified as 7S producers. The cells in
the droplets that showed antibody activity in both the mercaptoethanol
treated and the anti-7S treated but no activity in the doubly treated droplet
were classified as double producers.
The single cell techniques described above, although effective, were tedi-
ous with very limited screening power in terms of detecting rare antibody-
producers among a large excess of non-producers.
1.2. Hemolytic plaque assay
In 1963, Jerne and Nordin developed a plaque assay which enabled them
to enumerate rare antibody-forming cells in a mixed cell population. In this
assay, popliteal lymph nodes removed from rabbits immunized with sheep red
blood cells were processed to give a cell suspension. These lymphoid cells
together with agar and target erythrocytes were plated in a petri dish pre-
coated with a bottom layer of agar and were incubated for one hour. The
incubation allowed the lymphoid cells to secrete antibody which bound to the
sheep red blood cells (SRBC). Guinea pig complement was then added and the
petri dish incubated for another hour. At this stage, the complement caused
lysis of the sensitized red cells, resulting in plaques which were visible as small,
round areas of hemolysis against the uniformly red background. These plaques
could be seen with the naked eye or visualized through a low power dissecting
microscope. The importance of this technique was that literally millions of
cells could be screened quickly for the presence of rare antibody-forming cells.
A short time later, Ingraham and Bussard (lg64) introduced another local-
ized hemolysis in gel technique. They used carboxymethyl cellulose as the
thickening agent rather than agar, and microscope slides rather than petri
dishes. A mixture of lymphoid cells from immunized animals, guinea pig com-
plement and carboxymethyl cellulose containing SRBC was pipetted onto
microscope slides which were divided into two rectangular areas by the use of
gummed label paper. Coverslips were then placed on the slides and sealed
around the edges with melted vaseline.
Cunningham (lQ65) introduced a modification of the Jerne-Ingraham tech-
nique. His was a free suspension, monolayer technique requiring no supporting
medium. A mixture of antibody-producing cells, complement and target
erythrocytes was placed in shallow circular chambers on microscope slides.
The cell suspension settled at the bottom to form a monolayer. The chamber
was then covered with a coverslip, and sealed with melted vaseline. This tech-
nique was found to be more sensitive and offered better resolution than the
Jerne-Ingraham technique.
In investigations aimed at a detailed study of the morphology of single
antibody-forming cells, Cunningham, Smith and Mercer (lQ66) further
modified the technique for the purpose of micromanipulating the plaque-
forming cells, since in the above technique the coverslips made the plaque-
forming cells inaccessible. A shallow chamber was prepared by painting vinyl
plastic around the edges of a microscope slide and this chamber was then filled
with paraffin oil. A drop of a mixture of lymphoid cells from immunized
animals, SRBC and complement was then introduced under the oil with a fine
pipette. The cells formed a monolayer and the plaque-forming cells that were
identified could be removed with a micropipette attached to a micromanipula-
tor and examined under a light microscope for morphological studies.
The Jerne hemolytic plaque assay was thought to detect only those cells
secreting antibody of IgM class. Sterzl and Riha (1965) as well as Dresser and
Wortis (1965) showed that by adding anti-IgG sera, after primary incubation
with antibody-secreting cells, cells producing non-complement fixing antibody,
or antibody of low hemolytic efficiency could be detected. This technique was
further extended to the detection of plaque-forming cells of all classes and
subclasses by the use of appropriate antisera.
Mishell and Dutton (1967) who used the plaque assay to study primary
immune responses in vitro, used microscope slides rather than petri dishes, and
agarose instead of agar. This method was found to be more economical since
it required smaller amounts of reagents.
Cunningham and Szenberg (1968) introduced another modification of their
free suspension technique whereby the size of the chambers was increased for
greater screening power. They prepared microscope slides by using four strips
of double adhesive scotch tape to divide it into three equal parts. Coverslips
were then pressed on to form three chambers. These chambers were then filled
by capillary action with a mixture of lymphoid cells from immunized animals,
erythrocytes and complement and sealed with melted vaseline. Anti-Ig sera
was also added for indirect plaques.
Nossal, Bussard, Lewis and Mazie (1970) introduced an 'open system'
modification of the Ingraham-Bussard technique. This technique made the
plaque-forming cells accessible for micromanipulation. A mixture of lymphoid
cells from immunized animals, SRBC, complement and carboxymethyl cellulose
was pipetted onto coverslips which were then immersed in paraffin oil.
Kennedy and Axelrad (1971) introduced another monolayer plaque assay.
In this assay, advantage was taken of the fact that the surface of a plastic
petri dish is negatively charged. Poly-L-Iysine, which is positively charged,
was used to coat the negatively charged surface of the plastic petri dishes. A
monolayer of negatively charged SRBC was then bound on to the positively
charged poly-L-Iysine. A mixture containing the antibody-producing cells and
complement was then added and allowed to settle into a monolayer. By expos-
ing the petri dishes to gluteraldehyde vapour after plaque formation, per-
manent preparations could be made for radioautographic and morphological
studies which had not been possible with the other techniques.
Lefkovits (1972) introduced a plaque assay that could be performed in
microwell plates. In this test, spleen cells stimulated with heterologous red
cells were removed from microcultures and transferred with a replicator to
microwell plates containing bottom agar. The replicator could simultaneously
remove samples from 60 wells of a tissue culture plate and release them on an
assay plate (Lefkovits and Kamber, 1972). The droplets of cells were allowed
to soak into the agar and were then overlaid with top-agar containing red cells
and incubated. Complement was then added. This method had the advan-
tage of allowing a large number of samples to be screened as well as requiring
smaller volumes than the slide or petri dish method .
Kappler (lQ74) introduced a free suspension plaque assay that could be
done in microwell plates. SRBC, complement and antibody-producing cells
were added to each well of the microwell plate. The cell mixture settled at the
bottom to form a monolayer. Plaques were scored by viewing with a low
power stereoscopic microscope with indirect transmitted light.
Kissinger and Myl (lQg4) introduced a capillary glass microslide method.
The microslides were custom-made by Vitro-Dynamics and did not require
assembly like Cunningham chambers. The microslide method was found to be
as sensitive as the method of Cunningham. A mixture of SRBC, antibody-
secreting cells and complement was pipetted into the microslides through capil-
lary action . The microslides were then sealed with a paraffin-petrolatum mix-
ture. The plaques could either be counted under a low power microscope or
they could be electronically counted by the use of the Artek Systems Counter
Model QgO (Katz , Faulkner, Katz, Lindh, Leonhardt, Herr and Tung, lQ77).
The latter allows rapid, semi-automated counting of plaque-forming cells
directly from the slides on which they are developed, and depends on the
change in optical density that occurs when an area of red cells is lysed.
The techniques described above only allow the detection of anti-red cell
antibody. By artificially coupling proteins, polysaccharides, or hap tens , to red
blood cells, cells secreting antibodies to these could also be detected (Jerne ,
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Henry, Nordin, Fuji, Koros and Lefkovits, 1974). To detect cells secreting
antibody to antigens that could not be readily coupled to SRBC, Bagasara and
Damjanov (1982) described a latex bead technique. They used a bacterial
antigen that could not be coupled to SRBC but was readily adsorbed onto
latex beads. A mixture of antibody-secreting cells, SRBC, antigen-conjugated
latex beads, complement and agarose were poured onto slides and incubated.
It was postulated that plaques formed, when the antigen-antibody complexes
bound to latex beads, activated the complement which caused lysis of nearby
red blood cells.
1.3. Reverse hemolytic plaque assay
In 1974, Molinaro and Dray introduced the first reverse hemolytic plaque
assay (RHPA). SRBC were coated with anti-human Ig antibody and a mixture
of these with agarose and peripheral blood lymphocytes was plated on petri
dishes. Antiserum to human Ig (developer) and complement were added after
incubation. Plaques developed at the site of any antibody-secreting cell,
irrespective of the antigenic specificity, because the anti-Ig on the SRBC would
bind the human Ig which would in turn bind the anti-human Ig and this com-
plex would then activate the complement system. When the developing anti-
body was omitted from the assay, no plaques were found. Eby, Chong, Dray
and Molinaro (1975) later applied this technique for enumerating Ig-secreting
cells in non-immunized individuals as a measure of B-cell function.
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Ginsburg, Finkelman and Lipsky (1978) by using class-specific anti-Ig
(developing antibody) were able to determine the class of Ig secreted.
Gronowicz, Coutinho and Melchers (1976) described another RHPA . In
this assay, protein A from Staphylococcus aureus which binds to the Fe region
of IgG was used to coat red cells. The protein A-coated red cells were incu-
bated in petri dishes together with the antibody-secreting cells, agar, comple-
ment and the IgG fraction of an antiserum, specific for one or more classes of
antibody. The secreted Ig formed a complex with the corresponding IgG
molecules of the antiserum and these complexes bound to the protein A on the
red cells. The complexes activated complement resulting in lysis of the red
cells to which they were bound.
Bird and Britton (1979) later adapted the protein A technique to the
human system.
The RHP A described above usually incorporated agar or agarose in the
assay. Two groups introduced a fluid phase technique (Pryjma, Munoz, Virella
and Fudenberg, 1980; Beaudoin, Valet and Hebert, 1980). A mixture of pro-
tein A-coated SRBC, antibody-secreting cells, antiserum and complement was
pipet ted between two microscope slides held together by double-sided adhesive
tape. The slides were then sealed with paraffin .
Pang, Gatman, Drummond and Booth (1981) introduced a micromethod
form of the RHPA. A mixture of protein A-coated SRBC and lymphocytes
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was added to flat-bottomed 96-well microtitre plates which were spun at low
speed to give a monolayer of cells at the bottom of each well. After incuba-
tion, antiserum was carefully added to each well followed by another incuba-
tion, and then the addition of complement.
Librach and Mackay (1982) modified the micromethod further by using
the same microwell plates for the plaque assay that were used for culturing
cells. The microwell plates containing the antibody-secreting cells were centri-
fuged and the supernatant discarded by inverting the plates. The cells were
resuspended and to each well was then added erythrocytes, antiserum and
complement. The plaques were scored with a stereoscan microscope. In com-
paring the solid-phase and the liquid-phase system, it was observed that the
latter was the more sensitive assay (Wangel, Poikonen and Eskola, 1984).
The RHP A is still quite extensively employed by investigators for the pur-
pose of studying in vitro activation of human peripheral blood B lymphocytes
by such mitogens as pokeweed mitogen and Epstein-Barr virus (EBV), and for
enumerating individual sub populations secreting Ig of a specific isotype, allo-
type or idiotype by the use of appropriate antisera.
1.4. Enzyme-linked immunospot assay
In 1983, Czerkinski, Nilsson, Nygren, Ouchterlony and Tarkowski as well
as Sedgwick and Holt (1983) introduced a solid phase enzyme-linked immunos-
pot (ELlSPOT) assay, based on the principles of the enzyme-linked
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immunosorbent assay (ELISA) system, for enumerating specific antibody-
secreting cells as well as for quantitating the amount of antibody secreted.
Antibody-secreting cells were added to antigen-coated (eg. ovalbumin) petri
dishes. The dishes were then incubated and rinsed followed by the addition of
an anti-Ig serum conjugated to enzyme. Then, after incubation and rinsing,
an agarose-substrate solution was added to the dishes and immediately flicked
off to leave a thin film of gel. Where antibody-production had occurred, spots
appeared which were dark-brown or blue, depending on the chromagen used,
and which could be counted with the naked eye or under low magnification.
For quantitation of secreted antibody, all the steps performed were as
described for the immunospot assay, but instead of adding agarose-substrate, a
liquid solution of substrate was added to each dish. The samples were then
transferred to micro-ELISA plates and the absorbance values were recorded
with a multi-channel spectrophotometer.
Czerkinski, Tarkowski, Nilsson, Ouchterlony, Nygren and Gretzer (1984)
as well as Holt, Cameron, Stewart, Sedgwick and Turner (1984) also intro-
duced a reverse ELISPOT. Antibody-secreting cells were added to petri dishes
coated with anti-Ig, After a period of incubation, conjugate was added fol-
lowed by substrate.
Moller and Borrebaeck (1985) described a filter immunoplaque assay
(FIPA) capable of screening several hundred samples a day. In this assay,
antibody-secreting cells were incubated on antigen-coated nitrocellulose
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membranes in micro-filter plates or in petri dishes. The products of specific
antibody-producing cells were then detected by the addition of conjugated
secondary antibody and substrate.
The ELISPOT assay seems to be of equivalent or greater sensitivity to
existing plaque techniques and is especially useful in enumerating antigen-
specific Ig-secreting cells in which the antigen is difficult to couple to red cells.
Since it is not dependent on the use of complement-mediated lysis, it elim-
inates any errors due to the variation in susceptibility of target erythrocytes to
lysis. Other investigators have also introduced assays which are not dependent
on complement-mediated lysis. To mention a few, Pick and Feldman (1967)
introduced an autoradiographic technique. Microscope slides were coated with
a mixture of lymph node cells from immunized rats together with agarose.
The Ig secreted by the cells was precipitated by anti-Ig and revealed by radio-
labelled antigen. Moore and Calkins (1983) introduced an antibody-forming
cell focus assay (AFCF). The Ig secreted by cells was immobilized by the
anti-Ig used to coat petri dishes. Erythrocytes were then added to the petri
dishes which were incubated and then washed gently to remove any unat-
tached red blood cells (RBC). The antibody-secreting cells were revealed by
the formation of foci of intact erythrocytes around the Ig-secreting cells.
These methods are not as sensitive as the ELISPOT and are more time-
consuming and tedious to perform.
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1.5. Plaque assays using nucleated cells as target cells
In 1971, Fuji, Zaleski and Milgrom applied the plaque technique to
nucleated cells, using thymus cells [Thy-I) and lymphoblast (H-2) target cells
instead of red cells. The spleen cells from immunized mice, nucleated target
cells, and agar were spread evenly on microscope slides and incubated. The
slides were then flooded with complement, incubated and finally fan-dried and
fixed with ethanol. The plaques appeared as clear areas of localized cytolysis .
Nordin, Cerottini and Brunner (1971) described a similar assay in which
they used allogeneic tumor cells as target cells. After plaque formation, which
took 24 hours, the slides were fixed with ethanol and stained with Giemsa
stain. Giemsa stained the intact cells and not those that had been lysed.
Taylor and Bennett (1973) introduced a modification of this technique.
They stained the petri dishes with trypan blue after plaque formation, so as to
stain lysed cells preferentially.
Unlike the methods involving red cells as targets, the techniques devised
for nucleated target cells have never come into general use. A recent computer
search of the literature between 1970 and 1986 produced only five papers
where these methods had been used in research (Lake, 1976; Nakashima and
Lake , 1979; Nakashima, Mizoguchi, Kato, Nagase, Isobe, Saito and Suzuki,
1982; Nakashima, Clark, Lake, Kato, Nagase, Mizoguchi, Isobe and Saito,
1983; Mizoguchi, Nakashima, Isobe, Saito, Nagase, Kato and Shimokata,
16
1984).
1.6. Concluding remarks
In the 23 years, since the invention of the hemolytic plaque method by
Jerne and Nordin, that technique has been applied to virtually every problem
in cellular immunology. The use of red cells as targets has been the key
feature of most of these experiments. The far smaller number of publications
which involve the use of nucleated cells as targets, presumably reflects, in part
at least, the less satisfactory state of the latter technique. In this thesis, a
method using fluorescein-labelled EBV-transformed cells as targets is described.
It was felt that the sharp contrast between the live and dead cells, that is, the
fluoresceinated and the non-fluoresceinated (or alternatively, propidium
iodide-stained) cells, respectively, would provide a clearer and better definition
of plaques than the earlier methods.
1.7. Objectives
A plaque assay capable of detecting cells making anti-lILA antibody has
many applications and would be particularly useful to an investigator engaged
in making monoclonal antibodies to lILA antigens. It could be used to moni-
tor the frequency of specific antibody-forming cells in the blood of humans at
intervals after immunization or pregnancy; to monitor cellular manipulations
such as the effectiveness of an enrichment procedure for specific cells; to deter-
mine if there are any antibody-forming clones developing in post-immunization
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mixed lymphocyte cultures; to check the clonality of a cloned hybridoma cul-
ture; to monitor the frequency of specific antibody-forming EBV-transformed
cells as compared to the overall culture; to investigate the problem of the loss
of specific antibody-secreting clone(s) in a polyclonal EBV-stimulated culture
that usually occurs after a few weeks of the cells in culture. The most ambi-
tious application of this plaque assay would be to identify specific plaque-
forming cells and then to remove them by micromanipulation for cloning or
fusion.
The objectives of this study were:
(1) To develop a plaque assay against nucleated target cells using mouse
hybridorna cells that are known to secrete high levels of cytotoxic anti-
body.
(2) If this was successful, then to explore the possibility of adapting the
method to detecting human antibody-secreting cells, such as human
hybridoma cells, to see if specific plaques could be produced with these.
(3) To apply the plaque assay to one or more of the problems mentioned
above, if time permitted .
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CHAPTER 2
MATERIALS AND METHODS
2.1. Stains
Two stains were used in the plaque assay. Carboxyfluorescein diacetate
(CFDA, Molecular Probes Inc., 24750 Lawrence Road, Junction City, OR.,
U.S.A.) was used to stain living cells. Propidium iodide (PI, Sigma, St. Louis,
Missouri 63178, U.S.A.) was used to stain dead cells.
2.2. Target cells
2.2.1. Source
Epstein-Barr virus (EBV)-transformed cell lines from 11 adults were used
in these experiments (Table 1). All except GM3161 were produced in this
laboratory from patients or healthy individuals. GM3161 was obtained from
the Human Genetic Mutant Cell Repository (Camden, N.J. 08103, U.S.A.).
2.2.2. Procedure for preparing the cells for the assay
These cells were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate and
10% heat inactivated fetal calf serum (FCS, Flow Labs., Mclean, Virginia
22102, U.S.A.) at 37 0 C in a humidified CO2 incubator. No antibiotics were
used. They were harvested while in the log phase of growth and at greater
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Table 1
The BLA phenotypes of target cell lines used
Target Cell Line
lILA Phenotv pes
A B C DR DQ
E.A. 12 814 -- 23 wI
B.C. 1,2 5,?17 w3,w6 4,5 w3,w3
D.C. 3 ?5,15 w4,?w6 2,?w6 wI
E.C. 13 7- w6 2 wl-
M.C. 1,24 7,18 w4 2,3 wl,w3
K.H. 1,2 8 wl,- 3,4 w2,w3
C.A.K. 124 744 w26 25 wl w3
C.H.M. 1,2 8,40 w3 13 wl,w2
L.R. 3,w24 7,15 wI 2,w9 wI
T.P. 228 18 -- 24 wl w3
GM3161 1,2 12,- w3,- 2,2 wI
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than 90% viability as determined by phase contrast microscopy or by try pan
blue exclusion (section 2.6). They were counted in a Neubauer hemocytometer
and appropriate volumes were pipetted from the cultures for use in the assay .
They were centrifuged and washed twice in phosphate-buffered saline (PBS) ,
pH 7.4 at 500g for 10 minutes each and resuspended at a concentration of 15
million target cells per 1 ml of a working solution of CFDA. The CFDA work-
ing solution was made by adding 80 III of the stock solution (100 mg of CFDA
in 10 ml of acetone) to 10 ml of PBS. The cells were incubated at 37 0 C for 20
minutes and washed three times in PBS at 500g for 10 minutes each. The pel-
lets were then resuspended in appropriate volumes of PBS.
2.3. Antibody-secreting cells
2.3.1. Source
2.B.1A . Mouse
Nftd.Ml: Nfld.Ml is a locally produced mouse-mouse hybridoma
(Drover , Marshall and Younghusband, 1985). It resulted from a fusion
between immune spleen cells from a Balb/c mouse and SP2/0-AgI4, a non-
secreting mouse plasma cytoma (Shulman, Wilde and Kohler, 1978). It secretes
non-cytotoxic antibody of anti-HLA-DR4 specificity and of IgGI subclass .
Nftd.M2: Nfld.M2 is another locally produced mouse-mouse hybrid oma
(Drover , Marshall and Mervart, in preparation). It resulted from a fusion
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between immune spleen cells from a Balb/c mouse and SP2/0-AgI4. It
secretes cytotoxic antibody of anti-HLA-A2 and HLA-A28 specificity and of
IgG2a subclass.
2.B.1B . Human
Nfld.Bl: Nfld.Hl is a locally produced human-human hybridoma
(Drover, Codner, Fuad, Marshall, Mervart, Wasi and Yun , in preparation). It
resulted from a fusion between an EBV-transformed cell line from a recently
delivered multiparous woman and KR4 , a human fusion partner (Kozbor,
Lagarde and Roder, 1982). This human monoclonal antibody is of IgM class,
and only reacts significant ly with EBV-transformed B cell lines and not with
periph eral or umbilical cord blood T and/or B cells. At high dilutions , it
reacts with cell lines that carry HLA-DR2 and HLA-DQwl , however , the pre-
cise nature of the molecule(s) with which it binds has not yet been established.
EBV-transformed cells as antibody-secreting cells: These were
EBV-transformed cells made from B cells obtained from an immunized adult
male volunteer (W.H.M.). The immunization, which was fully approved by the
Human Investigations Committee, was done by injecting 5 x 107 peripheral
blood lymphocytes (PBLs) from another male volunteer (C.H.M.), intrader-
mally at four sit es on six occasions (March, 1983; April , 1983; June , 1983;
November , 1983; January , 1984; April , 1985). The PBLs were in 20% heat
inact ivated autologous serum in RPMI and 0.1 ml was injected at each site.
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W.H.M. was bled on Day 1, 4, 7, 11, 14, 19, 22, 25, 28, 32, 35, 39 and 42 fol-
lowing the sixth immunization in April , 1985. The B cells were then isolated
from these blood samples (section 2.8) and were transformed with EBV (sec-
tion 2.9). Thes e transformed B cells were used in the plaque assay as a source
of antibody-secreting cells.
2.3.2. Procedure for preparing the antibody-secreting cells for the
assay
The preparation of the antibody-secreting cells was the same as described
earlier for the target cells (section 2.2.2). The cells were resuspended in PBS
but were not labelled with CFDA.
2.4. Anti-lymphocyte serum
Anti-lymphocyte serum (ALS) was used in the initial experiments. It was
produced locally in 1974 for use as a positive control in lILA typing, by
immunizing a rabbit repeatedly with human thymus cells.
2.5. Antiserum
The anti serum used was a commercially available rabbit anti-mouse IgG ,
IgA and IgM (H + L) (Dako Labs . from Cedarlane Labs . Ltd . 5516-8th Line ,
R.R.2 Hornby, Ont., Canada) .
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2.6. Trypan blue exclusion
The trypan blue solution was prepared by adding 0.3 ml of 1% trypan
blue (prepared in water) to 0.7 ml of 2% EDTA buffer. To 0.1 ml of this solu-
tion was added 0.1 ml of cell suspension. After gently mixing, a small volume
was removed with a pasteur pipette and used to fill a Neubauer hemocytome-
ter. The chamber was then examined under a microscope and the percent via-
bility was determined by dividing the number of live cells (cells that excluded
trypan blue) by the total number of cells and multiplying it by 100.
2.7. Procedure for concentrating supernatants
Supernatant obtained from Nfid.H1 culture was concentrated using
Minicon-B15 Concentrators (Amicon Corp., Danvers., MA OHl23, U.S.A.)
which are disposable multiple ultrafilters. They consist of sample chambers
which are marked on the outside with graduation lines indicating the concen-
tration ratios. A sample can be concentrated up to 10o-fold. The superna-
tant was applied through the opening at the top of the sample chamber of the
miniconcentrator with a pasteur pipette and left to stand until the desired con-
centration was reached. The concentrated sample was then removed with a
pasteur pipette.
2.8. Isolation of B lymphocytes
Lymphocytes were isolated by the Ficoll/Hypaque density method
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(Boyum, Ig68) . All the manipulations were done using sterile technique.
Heparinized blood was diluted 1:2 in PBS and layered gently on top of Ficoll
Hypaque (Pharmacia, Dorval, Quebec, Canada, density : 1.077) at a ratio of 2:1
of blood to Ficoll in a 50 ml tube. The tub e was then centrifuged at 500g for
20 minutes. After centrifugation, the mononuclear layer was removed care-
fully from the interface with a pasteur pipette and put in a tube containing an
equal volume of Hank 's balanced salt solution (BSS) without calcium and mag-
nesium (Flow Labs .). The cells were centrifuged and washed twice in Hank 's
BSS at 400g for 10 minutes to remove the residual Ficoll and most of the pla-
telets and were then resuspended in culture medium (RPMI 1640 containing
L-glutamine, sodium pyruvate and 10% heat inactivated FCS) at a concentra-
tion of 5 x 106 lymphocytes per ml.
The B cells were then purified by the following procedure : to a sterile ,
polystyrene culture tube (12 x 75 mm, Fisher Scientific Co., Pittsburgh, PA
1521g, U.S.A.) was added 2 ml of cell suspension and 2 ml of neuraminidase
treated sheep red blood cells (NSRBC; Weiner , Bianco and Nussenzweig, Ig73) .
The tube was rotated on a rotator at medium speed for 15 minutes and then
centrifuged at 500g for 5 minutes. After centrifugation, half of the superna-
tant was removed and the pellet was resuspended gently with a pasteur
pipette. Approximately, 0.5 ml of Ficoll Hypaque was then layered under the
cell suspension and the tube was centrifuged at 350g for 20 minutes. The layer
at the interface containing the B cells was removed carefully and washed twice
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in culture medium for 10 minutes at 500g. Finally, the pellet was resuspended
in an appropriate volume of culture medium for transformation with EBV.
2.9. EBV-transformation
The B cells were resuspended at a concentration of 1 x 106 per ml. To
sterile Fisher snap top tubes (12 x 75 mm) were added 0.5 ml of the B cells
and 0.5 ml of 1/16 dilution of EBV, prepared from the EBV-transformed mar-
moset lymphoblastoid cell line B95/8 (Miller and Lipman , 1973) which was
kindly provided to us by Dr. M.J . Hobart, Cambridge, U.K. The tubes were
then incubated at 37 0 C in a CO2 incubator and fed after five days . All the
subsequent feedings were done twice a week by removing half of the superna-
tants with pasteur pipettes and replenishing them with fresh culture medium.
2.10. Complement dependent cytotoxicity
Compl ement depend ent cytotoxicity assay (CDC) was developed by
Terasaki and McClelland in 1964. The 6Q-well microtitre plates (Nun c Pro-
ducts , Roskilde, Denmark) used for the assay were prepared by the addition of
a drop of light paraffin oil to each well. One III of one of the following was
then added to each well under the oil with a graduated microsyringe (Hamilton
Co. Inc ., Whittier, California, U.S.A.).
(i) supernatant to be tested, or
(ii) 10% FCS in RPMI 1640, negative control, or
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(iii) ALS, positive control
Then 1 pI of target cells (2 x 106 per ml) was added to each well and the plates
were incubated at room temp erature. All incubations were done at room tem-
perature. After 1 hour, 5 pI of rabbit complement (HLA-ABC or DR rabbit
complement from Pel Fr eez, Brown Deer , Wisconsin 53223, U.S.A.) was added
with a multi syringe (Hamilton Co. Inc.) and incubated for another 2 hours.
Then 5 pI of a 5% eosin solution prepared in water (stain for dead cells) was
added and after 10 minutes, 5 pI of buffered formalin (40% formaldehyde solu-
tion titrated with KOH to pH 7.2) was added and the plates were incubated
for 30 minutes. Finally, paraffin oil was added and the wells were covered
with polystyrene planing slides (45 x 72 mm , Lux, Miles Scientific , Div. Miles
Laboratories Inc. , Naporville, IL. 60566, U.S.A.). The plates were read under
an invert ed microscope. The rea ction in each well was scored according to the
percent of cells that had been killed .
2.11. Cloning
Nfld.M2 was cloned twice during the course of the experiment. The clon-
ing was done by limiting dilution as described by Oi and Herzenberg (Hl80).
The cells were counted and diluted to give 230 hybrids per 4.6 ml of culture
medium. To each of 36 wells of a 96 well flat-bottomed plate (Linbro Inc.,
subsidiary of Flow Labs.) was add ed 100 pI of the diluted cell suspension to
give 5 cells/well. An additional 4 ml of culture medium was added to the
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remaining 1 ml cell suspension and 100 III of this was added to another 36
wells to give 1 cell/well. To the remaining cell suspension was added 1.4 ml of
the culture medium and the last 24 wells were plated with 100 III to give 0.5
cells/well. These plates were then incubated at 37 0 C in a humidified CO2
incubator. On day 3, 100 III of fresh culture medium was added to each well
and the plates were fed at 5 day intervals after that. Feeding was done by
removing half of the supernatants from the wells with pasteur pipettes and
replenishing them with fresh culture medium. When the cells were 50%
confluent, the supernatants were tested for the presence of antibody by CDC
(section 2.10). Wells found to be positive were transferred to 24 well plates
(Linbro Inc.). When they again achieved 50% confluency, they were
transferred to 50 ml culture flasks (Falcon, Div . Becton, Dickinson & Co.,
Oxnard, California 93030 U.S.A.).
2.12. The plaque assay
2.12.1. The petri dish method
5 x 106 fluorescein labelled target cells were used per petri dish (35 x 10
mm, Falcon). In LP3 tubes (10.5 mm x 63.5 mm, Victoria Gardens, Burgess
Hill, Sussex) were placed, a) 10 III containing 5 x 106 labelled target cells, b)
one of the following:
(i) 40 III of PBS, negative control, or
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(ii) 40 pI of ALS (1/16 dilution), positive control, or
(iii) 40 pI of supernatant at various dilutions from an overgrown cul-
ture of Nfld.M2 , or
(iv) 10 pI of Nfld.M2 hybridoma cells at various concentrations plus
30 pI of PBS
c) 0.25 ml of warm (45 0 C) 2 x BSS containing 0.2% DEAE-dextran (Sigma).
The tubes were then placed in a 45 0 C waterbath and 0.25 ml of warm (45 0 C)
1.4% agar (Bacto agar, Difco Labs., Detroit, Michigan, U.S.A.) was added to
each. The cell suspension from each tube was mixed well and quickly poured
into prewarmed petri dishes. When the agar solidified, the dishes were flooded
with culture medium and incubated at 37 0 C in the dark as were all subse-
quent incubations. After two hours, the medium was poured off and the plates
were flooded with rabbit complement (lILA-ABC complement) and incubated
for another 2 hours . The complement was then poured off and the dishes were
examined under epi-illumination in a Zeiss fluorescence microscope using an
interference filter transmitting at 450-490 nm, and a 520 barrier filter. The
lOx ocular and the 6.3x objective lenses were found to be satisfactory.
2.12 .2 . Slide method #1
This slide method was a modification of the method developed by Cun-
ningham and Szenberg in 1968.
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2.12.2A. Assembling microchambers
The chambers were prepared by placing strips of double- sided adh esive
tape (12 mm wide) at both ends of a microscope slide (75 x 25 mm , precleaned,
plain) and one at the centre, thus dividing the free surface into two roughly
equal areas. Coverslips (22 x 22 mm) were pressed onto each ar ea so that they
stuck firmly . Each one thus produced a chamb er that was approximately 22 x
19 x 0.1 mm. The capacity of each chamber was approximately 40-45 pI (Fig-
ure 1).
2.12.2B. The assay
The assay was performed by the following procedure: In LP3 tubes were
placed a) 10 pI of 2 x 106 labelled target cells, b) 10 pI of one of the following:
(i) PBS, negative control , or
(ii) Supernatant from an overgrown culture of Nfld.M2, positive con-
trol , or
(iii) Antibody-secreting cells at various concentrat ions
and c) 45 pI of complement. The tubes were then placed in a 45 0 C waterbath
and 20 pI of warm (45 0 C) 1.5% agar (prepared in water) containing 5x BSS*
and 0.5% DEAE-dextran was added to each . The cell suspension from each
*The error in the concent rat ion of BSS was discovered after the thesi s had been exam-
ined. The final concentration of BSS in the slides should have been Ix and it was not.
The cells did not app ear to be unduly affected by the hypertonic environment.
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chambers
~ ~
~ r-----l
microscope
'-slide
coverslips
Figure 1: Slide method #1
adhesive
tape
The two chambers on a microscope slide after assembly are shown . T he
chambers are filled with a pasteur pipette through the opening at the top or
bottom.
31
tube was then mixed well and quickly pip et ted int o th e two chambers of a
prewarmed slide with a pasteur pipette. One tube was used per slide. Th e
slides were incubated at room temperature for two hours in th e dark and th en
examined under a fluorescence microscope . When PI was incorporated in the
assay to stain for dead cells, then 8 III (1 mg Pl /rnl of PBS) was added to the
cell mixtures and the volumes of target cells and antibody-secreting cells were
cut in half . When antiserum was used in the experiment, then 5 III of
antiserum was added to the cell mixtures.
2.12.3. Slide method #2
2.12.3A. Assembling microchambers
The microscope slides were prepared as usual with adhesive tape. The
coverslip s were lined with a water repellent vinyl sheet (Easy-on Brand 'Light
Tack' Self-Adhesive obtained from a supermarket , designed for lining kitchen
surfa ces, paper documents, etc) and placed vinyl side down on the slides ; this
vinyl cover prevented the coverslips from adhering to the agar (Figure 2).
2.12.3B. The assay
The assay was done by the following procedure: In LP3 tubes were
placed a) 10 III containing 2 x 106 labelled target cells, b) 10 III of one of th e
following:
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coverslips lined with transparent
vinyl sheet
dried agar
Figure 2: Slide method #2
The photograph on the top illustrates the chambers with the coverslips lined
with the transparent vinyl sheet in place. The photograph on the bottom
shows the microscope slides after the removal of the coverslips and after the
agar has been dried.
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(i) PBS, negative control, or
(ii) Supernatant from an overgrown culture of Nfld.M2, positive con-
trol, or
(iii) Antibody-secreting cells at various concentrations
and c) 8 pI of PI. The tubes were then placed in a 45 0 C waterbath and 54 pI
of warm (45 0 C) 1.4% agar (prepared in water) containing 1.5x BSS· with
0.15% DEAE-dextran was added to each. The cell suspension from each tube
was mixed well and then pipetted into the two chambers of a prewarmed slide.
After a few minutes, giving the agar time to solidify, the coverslips were gently
removed taking care not to disturb the layers of agar on the slides. The slides
were flooded with culture medium and incubated for two hours. All incuba-
tions were done at room temperature and in the dark. The medium was then
poured off and the slides were flooded with complement (lILA-ABC or DR
complement). After another two hours, the complement was poured off and
the slides were dried with an electric hot air dryer resulting in permanent
preparations (Figure 2). The slides were then examined under a fluorescence
microscope or stored in the dark in microscope slide folders and examined at a
later date. When antiserum was used, the slides were flooded with antiserum
and incubated for two hours before the addition of complement. The rest of
the procedure was the same as before.
• refer to footnote on page 29.
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2.12.4. Plaque size
To measure plaque size, a grid containing 100 equal size squares within a
large square was inserted into the eyepiece of the microscope. Using a stage
microm eter, the squar es on this grid were calibrated and found to measure 0.8
mm on each side, when the microscope was set up with a 6.3x obje ctive and a
12.5x ocular . Plaques were then superimposed on the grid , one at a time, and
their diameters measured in relation to the squares on the grid. Some 40-50
plaque diameters were measured. In some experiments, both plaque size and
% lysis were scored (Tables 4 and 6). In these cases, mainly confluent plaques
were present, but the outline of the plaques was often sufficiently preserved for
approximate diameters to be scored .
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CHAPTER 3
RESULTS
The results are described under five main headings, 3.1-3.5, and are given
in more or less chronological order as the technique was developed and
evaluated. After describing the principle in section 3.1, a series of exploratory
experiments is described in section 3.2 in which labelled target cells were
plated in petri dishes. In these experiments, attempts were made to lyse the
target cells with anti-lymphocyte serum, monoclonal antibodies, and lastly
hybridoma cells. The second set of experiments, described under section 3.3,
reveal the trial and error development of a plaque method done using micro-
scope slides and coverslips to enclose small chambers. A modification of this
method using two dyes was introduced quite late and the results are given in
section 3.3.8. Due to an unexpectedly low yield of plaques, some further exper-
iments were done to try to trace the possible cause(s) of damage to the
antibody-forming cells during processing. Under section 3.4, a second version
of the slide method is described in which the covers lips were removed from the
agar-bound cell suspension after the agar had solidified, so that a second anti-
body and complement could be added directly to the surface of the prepara-
tion after a period of incubation of the target cells with the hybridoma cells.
Experimental modifications, at this point, including the drying procedure
proved to be advantageous. In a final section, 3.5, the technique was put to
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use to answer questions concerning the need for recloning of Nfld.M2 , th e pos-
sibility of adapting the technique to dete ct human antibody-secreting cells
(ASC), and concerning the use of this technique to detect plaqu es with a
mouse hybridoma producing a non-complement fixing, IgGI antibody.
3.1. Principle
Carboxyfluorescein diacetate (CFDA) formed the basis of the plaque
assay. CFDA penetrates most mammalian cells and, upon hydrolysis by the
est erases within the cell, is converted to fluorescein (Rotman and Papermaster,
1966) which fluoresces green under a fluorescence microscope. Here, Epstein-
Barr virus (EBV)-transform ed cells which were used as targets were labelled
with CFDA . The procedure is described in materials and methods , section
2.2.2. The cells remained alive and intact after this procedure. The principle
behind the plaque assay was that upon lysis, the target cells would release
their fluorescein and become invisible . This would result in lytic plaques that
could be seen as clear areas surrounded by a lawn of green fluorescing cells.
During the course of the experiments, the use of another stain, propidium
iodide (PI), to label dead cells was started. Cells stained with PI appear
orange-red under the same microscopic conditions. The plaques could then be
visualized as orange-red areas surrounded by green fluorescing cells. This two
stain method was originally introduced by Bruning, Claas, Kardol, Lansbergen,
Naipal and Tanke in 1982 for the purpose of automated reading of HLA typ-
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ing plates and for screening of antibodies with the microcytotoxicity assay.
3.2. The petri dish method
The first experiments to develop a plaque method were done in petri
dishes. The technical details are described in materials and methods, section
2.12.1. Before looking for plaques, it was necessary to establish an optimal
concentration for the target cells and to show that lysis of these target cells
did indeed result in release of fluorescein and consequently fading of the target
cells (3.2.1, 3.2.2, 3.2.3)
3.2.1. Concentration of target cells
The concentration of target cells (C.H.M.) was varied from 1 x 106 to 1 x
108 per petri dish in order to determine the concentration that gave the most
confluent layer with an even distribution of cells. The petri dishes were set up
without antibody and complement. It was found that high concentrations of
cells gave a very dense layer of cells and, in some areas, clumping was also
observed. Low concentrations of cells resulted in a layer which was very
sparsely populated with gaps between cells. The optimal density of target cells
for the petri dish method was determined to be 5 x 106 per petri dish. This
gave an appearance similar to figure 3 (no photographs were taken for the
petri dish method) and this concentration was used in subsequent experiments.
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3.2.2. Experiments with anti-lymphocyte serum
The aim of these experiments was to observe target cell lysis and to deter-
mine if cell lysis was sufficiently visible to be detectable in a plaque. Since ear-
lier attempts to produce plaques with Nfld.M2 hybrids had been unsuccessful
(data not shown), it was necessary to start at a very basic level. Anti-
lymphocyte serum (ALS) was used because it is known to be cytotoxic for lym-
phocytes in the presence of complement. In three separate experiments, serial
dilutions of ALS, ranging from undiluted to 1/128 were added to petri dishes,
along with target cells (C.B.M.). The dishes were flooded with complement
after incubation. It was found that ALS did indeed lyse the target cells and in
a dose dependent manner, with dilutions below 1/16 giving 95-100% lysis
(similar to figure 4) and dilutions above that giving progressively less lysis
until, at 1/64, the dish looked no different from an untreated control. The
lysed cells were still visible under the fluorescence microscope and looked like
pale 'ghostly' versions of the previously brightly fluorescing cells.
3.2.3. Experiments with supernatants from Nfid.M2 cultures
Since the cytotoxicity of ALS was clearly demonstrated in the previous
experiments, it was important to see if Nfld.M2 antibody was similarly cyto-
toxic. Supernatant from an overgrown Nfld.M2 culture was known to be cyto-
toxic in complement dependent cytotoxicity (CDC), in a regular cytotoxicity
assay performed in Terasaki plates (materials and methods, section 2.10) with
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a titre of 1/128 (1 pi of supernatant was used per 2 x 103 cells per well).
Hence, this supernatant was similarly titred in the petri dish method to deter-
mine if the results were comparable. In two separate experiments, petri dishes
were set up with serial dilutions of supernatant ranging from undiluted to
1/128, plus target cells (C.H.M.). Complement was added after incubation.
The supernatant was found to be cytotoxic with a titre of 1/8 with 95-100%
lysis (40 pi of supernatant was used per 5 x 106 cells). Taking into considera-
tion the number of target cells and the volume of supernatant used for each
method, the two methods appeared to be of similar sensitivity.
3.2.4. Experiments with hybridoma cells from Nfld.M2 cultures
With the cytotoxicity of Nfld.M2 antibody established, an attempt was
once again made to produce plaques, using Nfld.M2 hybridoma cells. In a
series of experiments, the petri dishes were set up with concentrations of hybri-
doma cells ranging from 1 x 103 to 5 X 106 per petri dish plus target cells
(C.H.M.). Complement was added after incubation. The results are summar-
ized in table 2. At a ratio of 1:1 of target cells to hybridoma cells, complete
lysis was seen and as the concentration of hybridoma cells decreased, so did
target cell lysis. At hybridoma cell concentrations less than or equal to 1 x 104
per petri dish, no lysis was seen. In all these dishes, plaques were not detect-
able. The interpretation of these results was that perhaps the target cell layer
was too thick so that any small area of lysis was probably obscured by intact
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Table 2
Degree of lysis of target cells with decreasing
concentrations of Nfld.M2 hybridoma cells
(petri dish method)
Concentration of Hybridorna Cells Degree of Lysis»
5 x 106 ++++
1 X 106 ++(+)
5 x 105 ++
1 X 105 +
5 X 104 (+)
1 x 104
5 X 103
1 X 103
* ++++
+++(+)
+++
++(+)
++
+(+)
+
(+)
approx. g5-100% target cell lysis
approx. 85-g0% target cell lysis
approx. 75-80% target cell lysis
approx. 60-70% target cell lysis
approx. 50-55% target cell lysis
approx. 35-45% target cell lysis
approx. 20-30% target cell lysis
approx. 10-15% target cell lysis
less than 10% target cell lysis
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cells present above and/or below the lysed cells. The approach that seemed
appropriate to overcome this was to use microscope slides instead of petri
dishes so that a thinner layer of target cells could be obtained.
3.3. Slide method #1
The slide method was a modification of the method developed by Cun-
ningham and Szenberg in lQ68. It was hoped that these chambers of defined
depth would allow thinner layers of target cells to be formed, in which lysis
would be more easily visible.
3.3.1. Capacity of the chambers
The chambers were prepared as described in materials and methods, sec-
tion 2.12.2A. Measured volumes of liquid were then delivered into the
chambers and the capacity of each chamber was determined to be 40-45 pI giv-
ing a slide capacity of approximately 80-g0 pI.
3.3.2. Concentration of target cells
The optimal target cell concentration had to be determined again for this
method. The slides were set up with concentrations of target cells (C.R.M.)
ranging from 1 x 105 to 1 X 107 per chamber and without antibody or comple-
ment. A monolayer of target cells was obtained and 1 x 106 was determined to
be the optimal target cell density per chamber of a slide (figure 3).
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Figure 3: Negative control, slide method #1
Photomicrograph of a monolayer of fluorescein-stained target cells (C.H.M.)
obtained with a density of 1 x 106 cells per chamber. Magnification: 63x
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3.3.3. Complement volume
Since the capacity of each chamber was limited, it was necessary to deter-
mine the minimum volume of complement required for target cell lysis. In two
separate experiments, the slides (i.e. two chambers) were set up with volumes
of complement ranging from 5 pI to 65 pI per slide along with target cells
(C.H.M.) and Nfld.M2 antibody. Little or no lysis was found in the slides con-
taining less than 30 pI of complement. In slides containing 40 pI or more of
complement, 95-100% lysis was observed. Hence, 45 pI of complement per
slide was used in subsequent experiments.
3 .3. 4. Incorpor ation of ag ar
The slide method was originally set up as a liquid monolayer. This was
later modified to a semi-solid monolayer, because it was observed that when
the slides were set up with various concentrations of Nfld.M2 hybridoma cells
ranging from 5 x 102 to 2 X 105, target cells (C.H.M.) and complement and
incubated at 37 0 C, the target cells became agglutinated. This made the detec-
tion of plaques impossible. Since agglutination was not seen in the negative
controls, it was attributed to the fact that the antibody-coated target cells
which were in fluid suspension, moved about, thus coming into contact with
each other and resulting in agglutination. It was thought that if agar was
incorporated in the assay, it would provide a semi-solid support for the target
cells, and thus inhibit their motility.
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It was necessary to determine the concentration of agar that would ensur e
easy filling of th e chambers and 'an even distribution of cells without clumping.
In four separate experiments, slides were set up with concentrations of agar
ranging from 0.1% to 1% per slide , along with target cells (C.H.M.), Nfld.M2
hybridoma cells and complement. It was found that a final concentration of
agar in the cell mixtures of approximately 0.3% per slide was sufficient to
allow the cell mixtures to be delivered easily into the chambers and to produce
a satisfactory monolayer of target cells. At concentrations lower than 0.3% ,
the agar was too fluid and movement of the target cells could be observ ed
under the microscope if the slides were disturbed in any way while viewing.
One problem that was encountered with the use of agar was that if the slides
were cold, the agar would set while the chambers were being filled and this
result ed in uneven monolayers. Pre-warming the slides eliminated this prob-
lem.
3.3.5. Non-speclfle leaking of fluorescein
It was observed in the slide method, in both the negative controls (no
Nfld.M2 hybridoma cells added) and the experimental slides (with Nfld.M2
hybridoma cells), that the live target cells were spontaneously losing some of
their fluorescence and were fading during the incubation at 37 0 C. This was
not noticed in the petri dish method, perhaps due to the multiple target cell
layers. Spontaneous leaking out of fluorescein from lymphocytes has been
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observed by other investigators (Bodmer, Tripp and Bodmer, 1967). These
authors suggested that this non-specific leaking out of fluorescein is an energy
dependent process, probably connected with an active transport mechanism.
They showed that this leaking at 37 0 C could be prevented by the use of meta-
bolic inhibitors such as potassium cyanate and sodium azide.
If the leaking out of fluorescein involves an active transport mechanism
which requires energy, it was thought that incubating the slides at a lower
temperature, such as room temperature, might slow down the process, and
hence reduce or completely eliminate this loss of fluorescein from target cells.
In two separate experiments, two sets of slides were set up with target cells
(C.H.M.), Nfld.M2 hybridoma cells and complement. One set of slides was
incubated at 37 0 C and one at room temperature. At room temperature, the
loss of fluorescein was considerably reduced. Also, fortunately , no appreciable
difference was observed in the degree of complement dependent lysis between
the slides incubated at 37 0 C and the ones incubated at room temperature.
Therefore, all the subsequent incubations were done at room temperature.
3 .3 .6 . E xperime nts using v arious target cells w ith Nfld.M2 antibody
The following experiments were done to ensure that the observed cytotox-
icity of Nfld.M2 antibody was specific for cells having the phenotype HLA-A2
and A28 and not due to some non-specific factor present in Nfld.M2 cultures or
else some artefact produced by the plaque assay that resulted in target cell
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lysis. In two separate experiments, various target cells of different HLA pheno-
types (table 1) were set up on slides along with complement and supernatant
from an overgrown culture of Nfld.M2. As can be seen from table 3, in all th e
slides containing HLA-A2 positive target cells, lysis was observed, whereas in
the ones containing HLA-A2 negative target cells, no lysis was seen. In
another two experiments, Nfld.M2 hybridoma cells were used instead of sup er-
natant. Slides were set up with 1 x 106 hybridoma cells per slide together with
the various target cells and complement. The results were qualitatively identi-
cal, with the hybridoma cells leading to 95-100% lysis only when the target
cells expressed A2 or A28.
3.3.7. Experiments with hybridoma cells from Nftd.M2 cultures
After optimizing all the parameters of the slide method, an attempt was
once again made to produce plaques with Nfld.M2 hybridoma cells. The pur-
pose of these experiments was to see if individual plaques could be produced
with low concentrations of hybridoma cells. In a series of experiments, concen-
trations of hybridoma cells, ranging from 5 x 102 to 1 X 106 per chamber were
set up on slides along with target cells (C.H.M.) and complement. It was
found that at a concentration of hybridoma cells of 1 x 106 per chamber, com-
plet e lysis (95-100%) was observed, whereas definite but confluent plaques were
seen at concentrations of 1 x 105 per chamber. These are shown in figures 4
and 5 respectively. At concentrations lower than 1 x 105, individual plaques
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Table 3
HLA speelflclty of Nfld.M2 demonstrated as
lysis of target cells using slide method #1
T arget Cell Line HLA-A Phenotype Degree of Lvsis»
E.A. 1,2 ++++
B.C. 1,2 ++++
D.C. 3
E.C. 1,3
M.C. 1,24
K.H. 12 ++++
C.A.K. 1,24
C.H.M. 1,2 ++++
L.R. 3 w24
T.P. 2,28 ++++
* ++++ approx. 95-100% target cell lysis
less than 10% target cell lysis
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Figure 4: Total target cell lysis, slide method #1
Approximately Q5% lysis of the target cells by Nfld.M2 hybridoma cells at a
concentration of 1 x 106 cells per chamber is shown. The lysed cells are
faintly visible in the photomicrograph. Magnification: 63x.
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Figure 6: Confluent plaques, slide method #1
Confluent plaques made by Nfld.M2 hybridoma cells at a concentration of 1 x
105 cells per chamber are shown. Magnification: 63x.
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were observed (figure 6). The sizes of the plaques usually ranged from 0.1-0.4
mm in diameter. Plaque sizes of 0.5-0.6 mm were also observed but very
rarely and they were thought to probably result from the secretion of antibody
by two or more neighbouring plaque-forming cells (PFC). Although, the bigger
plaques (0.3-0.4 mm) were clear and easily identified (figure 6,) the smaller
ones (0.1-0.2 mm) were hard to distinguish from the normal background varia-
tion in the distribution of the target cells. In order to overcome this problem,
the use of another stain, PI, was started. It was hoped that PI would enhance
the appearance of small plaques in that they would stand out better from the
background of target cells.
3.3.8. Addition of Propidium Iodide
These experiments were set up in order to determine the concentration of
PI that gave good staining of dead cells. In three separate experiments, slides
were set up with volumes of PI ranging from 1 pI to 10 pI per slide at a con-
centration of 1 mg/ml along with target cells (C.H.M.), Nfld.M2 hybridoma
cells and complement. It was found that about 8-10 ul of PI per slide gave
good staining of dead cells. Below 8 ul, the staining was too faint. Therefore,
8 pI per slide was used in subsequent experiments. The addition of PI did
indeed make it easier to distinguish small plaques which were usually clear and
distinct provided the background of target cells was even and of high viability
and the PI staining was good. If the viability of the target cells was low, then
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Figure 6: Single plaque, slide method #1
A single plaque made by a Nfld.M2 hybridoma cell at a concentration of 1 x
104 cells per chamber is shown. Magnification: 63x.
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the high background of PI-stained cells made it difficult to detect small
plaques. The plaques ranged from 0.1-0.4 mm in diameter and usually con-
tained 15 or more dead cells depending on the size of the plaque. There was
usually no intervening live cell visible at the centre of a plaque . The plaques
observed were similar to those shown in figures 7 and 8 which are the result of
slide method #2.
3.3.9. Number of Nftd.M2 hybridoma cells versus number of plaques
The purpose of this experiment was to see if the number of plaques
obtained was proportional to the number of Nfld.M2 hybridoma cells plated.
In a series of experiments, slides were set up with concentrations of hybridoma
cells ranging from 6.3 x 102 to 8 X 104 per chamber along with target cells
(C.H.M.), complement and PI. The plaques were subsequently counted by
scanning entire chambers, using a 6.3x objective. This was relatively fast and
easy , taking 2-5 minutes for an average plaque density. Up to approximately
1500 plaques per chamber could be counted with accuracy. A higher number
resulted in confluency and consequently less accuracy in counting. When the
concentration of hybridoma cells was plotted against the number of plaques, a
straight line relationship was observed (figure g). This experiment was
repea ted a number of times and it was found that although a straight line rela-
tionship was observed each time , the slope of the graphs varied, that is, the
number of plaques obtained for the same number of hybridoma cells varied
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Figure 7: PI staining of dead cells, slide method #2
Five plaques made by Nfid.M2 hybridoma cells at a concentration of 5 x 103
cells per chamber, containing PI-stained dead cells (red) are shown. This pho-
tomicrograph illustrates the high viability of the background of target cells.
Magnification: 63x.
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Figure 8: PI staining of dead cells, slide method #2
The PI-stained dead cells in the cent er of the plaque are more clearly visible
because of the high magnification (160x).
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Graph showing the number of plaques obtained in one experiment versus th e
number of Nfld.M2 hybridoma cells plated.
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from day to day.
Another unexpected finding was that the number of plaques observed was
considerably less than th e number of hybridoma cells plated (usually less than
5%). This discrepancy could have been due to the experimental manipulations
which may have been altering the viability or function of the hybrids, and in
particular, the warming to 45 0 C could have been potentially damaging,
although the target cells usually appeared to be of high viability. In order to
investigate this problem, two sets of experiments were performed; one to inves-
tigate the question of viability after exposure to 45 0 C and the other to investi-
gate the effect of 45 0 C on antibody secretion.
3.3. 9A . Effect of 45•C on the viability of hybridoma cells
In this experiment, several tubes containing the same number of Nfld.M2
hybrid oma cells were exposed to 45 0 C for various lengths of time ranging from
o to 60 seconds and the viability was subsequently determined by the trypan
blue exclusion test as described in materials and methods, section 2.6. It was
found that the viability decreased by approximately 16% from 0 seconds to 60
seconds . From 0 to 15 seconds , there was a decrease in viability of approxi-
mat ely 5%. In the actual experiments, the hybridoma cells are exposed to
45 0 C for approximately 10-15 seconds . Therefore, the effect of this tempera-
tur e on viability appeared to be minimal.
3.3. 9B . Effect of 45' C on antibody secretion
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In this experiment, Nfld.M2 hybridoma cells were washed twi ce and 10 pi
aliquots containing 5 x 105 cells were placed in sever al tubes. One tube was
spun down immediately and the supern ata nt remov ed. Th e oth er tub es were
exposed to 45 0 C for vari ous lengths of time ranging from 0 seconds to 60
seconds and were then incubated for two hour s and centrifuged. The superna-
tant from each tube was set up on slides along with targ et cells (C.R.M.), com-
plement and PI. It was found that the supernatant removed from the tube
that was centrifuged immediately did not give any lysis. The other tubes all
gave approximately 70-80% target cell lysis. Therefore, antibody secretion
did not seem to be unduly affected by exposure of the hybridoma cells to
45 0 C for these periods of time .
3.3.10. Effect of anti-immunoglobulin antiserum (slide method #1)
The purpose of these experiments was to determine if the addition of
antiserum would facilitate target cell lysis by enhancing the complement fixing
ability of Nfld.M2 antibody and hence increase the number of plaques. In a
series of experiments, slides were set up with serial dilutions of antiserum (rab-
bit anti-mouse IgG, IgA and IgM) ranging from 1/25 to 1/3200 per chamber
together with target cells (C.R.M.), Nfld.M2 hybridoma cells ranging from 5 x
102 to 1 X 105, complement and PI. The effect shown in table 4 was observed
at a hybridoma cell concentration of 1 x 104 per chamber. Similar results were
obtained at hybridoma cell concentrations ranging from 1 x 104 to 5 X 104 per
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Table 4
Effect of serial dilutions of anti-Ig antiserum (As)
on the number and size of plaques formed
(slide method #1)
Dilution of As" Degree of Lvsis'' Plaque Size"
0 ++ 0.1-0.3 mm
1/25
1/50 (+)
1 100 +(+) 0.1-0.2 mm
1 200 ++ 0.1-0.3 mm
1 400 +++ confluent
1 800 +++ confluent
1/1600 ++ 0.2-0.4 mm
1/3200 + 0.1-0.2 mm
a antiserum used was rabbit anti-mouse IgG, IgA, IgM
(H+L).
b Nfld.M2 hybridoma cells were used at a concentration
of 1 x 104 cells per chamber of a slide.
++++ approx. 95-100% target cell lysis
+++(+) approx. 85-90% target cell lysis
+++ approx. 75-80% target cell lysis
++(+) approx. 60-70% target cell lysis
++ approx. 50-55% target cell lysis
+( +) approx. 35-45% target cell lysis
+ approx. 20-30% target cell lysis
(+) approx. 10-15% target cell lysis
less than 10% target cell lysis
C some plaque sizes are not given because either there
were no plaques present or they were confluent.
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chamber. At these cell concentrat ions, many plaques , alth ough not confluent,
were observed without the addition of anti serum . The addition of certain dilu-
tions of antiserum (1/400-1/800) resulted in the plaqu es becoming confluent .
At cell concentrations higher than 5 x 104 per chamber, th e plaque s were
confluent without the addition of antiserum, therefore, th e effect of antis erum
could not be det ermined. At cell concentrations lower than 1 x 104, few
plaques were observed without the addition of antiserum and the addition of
antiserum did not have any measurable effect . An inhibitory effect was
observed with high concentrations of antiserum at all cell concentrations. The
hybridoma cell concentrations at which an effect could be observed by the
addition of antiserum varied from assay to assay depending on the number of
PFC present per number of hybridoma cells plated.
In these experiments the anti-Ig was present right from the start and
therefore, as soon as the antibody was secreted, the interaction with anti-Ig
began. The inhibition effect may be due to the fact that the anti-Ig, which
was present in excess, formed immune complexes with the secreted Ig near the
PFC, thus inhibiting its diffusion towards the target cells. The enhanced tar-
get cell lysis seen at certain hybridoma cell concentrations could be due to the
fact that the PFC, which were present at high concentrations, tended to be at
close proximity to each other. Therefore, the secreted antibody, present at
high concent rat ions, probably formed soluble complexes with the anti-Ig (when
optimally diluted) near the PFC and diffused towards the target cells where
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the Ig-anti-Ig complexes activated the complement and caused target cell lysis.
It was thought that if anti-Ig was added later as in a classical indirect system ,
then this problem would be avoided because the secret ed antibody would have
a cha nce to bind to the target cells before the addition of anti-Ig. However ,
since experiments had, up to this point , been done in closed chambers , this
modification could not be made without altering the entire technique. Such a
modification is described in the next section.
3.4. Slide method #2
Slide method #2 was a modification of method #1. It was devised so
that anti-Ig could be added after the hybridoma cells had been incubated with
the target cells.
3.4A. Lining of the covers/ips
In order to add the anti-Ig later, the coverslips had to be removed so that
the surface of the agar layer could be exposed. Initially, an attempt was made
to remove the coverslips after setting up the slides in the usual way. This did
not work because the agar tended to adhe re to the coverslips and any attempt
at removing the covers lips resulted in tearing of the agar . It appeared neces-
sary to line the coverslips with something that would prevent the agar from
adhering to them. A transparent vinyl, self-adhesive sheet which was origi-
nally designed for covering kitchen surfaces, important documents, etc . was
used for this purpose. This sheet was cut in squares slightly larger than the
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coverslips. The coverslips were then placed on the adhesive side of each square
which was then trimmed to the size of the coverslip . The microscope slides
were assembled as usual and the lined coverslips were placed vinyl side down
on the slides . The slides were then set up and after giving th e agar sufficient
time to solidify , the coverslips were gently removed. Although the coverslips
came off nicely, without tearing the agar, the agar layer was too loose and
easily deformable and tended to come off the slides when the slides were
flooded with medium. The concentration of agar was evidently too low and
had to be increased . In a series of experiments, done to determine the
appropriate concentration, slides were set up with concentrations of agar rang-
ing from 0.4% to 2% per slide plus target cells (C.R.M.). After giving the agar
time to solidify, the coverslips were removed. It was found that a final concen-
tration of agar of approximately 0.8% per slide formed a nice layer that did
not come off the slides after the coverslips were removed and the slides were
flooded with medium.
3.4B. The drying procedure
A hot air dryer was used to dry the agar on the slides after the final incu-
bation. It was found that this drying procedure did not affect the fluorescence
in any way. In fact, this modification has several advantages over the original
slide method. One disadvantage of slide method #1 was that quenching of the
fluorescence would occur if the slides were examined for too long or at a high
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magnification, or if th ey were left overnight. This was inconvenient, especially
if repeated examination of a slide was necessary , for example , when determin-
ing the diameters of the plaques. With this new method, the preparations
were found to be permanent and plaques could be examined repeatedly, under
bright illumination, with virtually no quenching and no det ectable det eriora-
t ion. This was an advantage since the slides could be looked at any time , long
after the conclusion of the experiments. They could be stored easily in the
dark in a slide box.
3.4.1. Complement titration
In order to avoid waste of complement by flooding the slides with need-
lessly high concentrations, complement was titred out in two separate experi-
ments. Slides were set up with target cells (C.H.M.) , Nfld.M2 hyb ridoma cells
and PI. Serial dilutions of complement ranging from undiluted to 1/128 per
slide were added after incubation. The complement titred out at 1/4 and this
dilution was used in subsequent experiments.
3 .4 .2 . N u m ber of hybridoma cells ver sus number of plaques
As for slide method #1 (section 3.3.9), the relationship between the
number of hybridoma cells plated and plaques formed was determined for slide
method #2. In th ree separate experiments , the slides were set up with target
cells (C.H.M.), recloned Nfld.M2 hybridoma cells ranging from 6.3 x 102 to 8
X 104 per chamber and PI. Complement was added after incubation. The
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plaques were subsequently counted and plotted against the number of hybri-
doma cells (this data was taken from the cloning experiment, clone 1 at day
13, section 3.5.1, figure lla). A straight line relationship was observed as
shown in figure 10. As for slide method #1, there was a daily variation in the
slope of the graph i.e. the percent of hybridoma cells which were actually
secreting antibody was not constant.
3 .4 .3 . Comparison of slide method #1 with slide method #2
The two slide methods were set up in parallel to compare their sensitivity
in terms of detecting PFC. In three separate experiments, the two methods
were set up with target cells (C.H.M.), Nfld.M2 hybridoma cells ranging from
6.3 x 102 to 8 X 104 per chamber, complement and PI. The total incubation
time for both methods was the same. The plaques were subsequently counted
and calculated to give plaques/5000 hybridoma cells. The results are summar-
ized in table 5. It was found that slide method #2 was approximately 5-10x
more sensitive than slide method #1. In the three experiments, on an average ,
the ratio of PFC for slide method #1 to slide method #2 was 1:4.8, 1:4.7,
1:10.2, respectively.
3.4.4. Effect of anti-immunoglobulin antiserum (s lid e method # 2)
In a series of experiments, the slides were set up with target cells
(C.H.M.), Nfld.M2 hybridoma cells ranging from 5 x 102 to 1 x 105 per
chamber and PI. After incubation, the slides were flooded with serial dilutions
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Figure 10: Number of plaques formed as a function of number of
hybridoma cells plated (slide method #2)
Graph showing the number of plaques obtained in one experiment versus the
number of NOd.M2 hybridoma cells plated.
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Table 6
The number of plaques formed with Nfld.M2
hybrldoma cells are compared for
slide method #1 and method #2
Experiment # Plaques/5000 Hybridoma Cells
Method #1 I Method #2
1 11 I 53
2 17 I 80
3 27 I 275
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of rabbit anti-mouse IgG, IgA and IgM ranging from 1/25 to 1/3200 per slide.
Complement was added after incubation. When the slides were examined, no
plaques were seen in the slides to which antiserum had been added. In subse-
quent experiments, the antiserum was diluted from 1/200 to 1/3,246,800 and
the results are summarized in table 6. As for method #1, a prozone effect and
an optimal concentration ranging from 1/409,600 to 1/819,200 was observed
and only at certain cell concentrations. The results shown in table 6 were
observed at a hybridoma cell concentration of 5 x 103 cells per chamber. Simi-
lar results were obtained at hybridoma cell concentrations ranging from 5 x
103 to 2 X 104 per chamber and this was subject to variation from assay to
assay as for method #1. Therefore, adding the antiserum after prior incuba-
tion of the slides was not an improvement over adding it at initial preparation
of the slides. The extraordinarily high dilutions needed to produce an enhanc-
ing effect and the possible mechanism for the prozone effect are considered
later in the 'discussion' section.
3.5. Some applications of the plaque assay
3.5.1. Cloning of Nftd.M2 hybrids
Nfld.M2 hybridoma cells had been cloned twice during the early stages of
the experiments but not since then. Therefore, there was a possibility that a
majority of the hybridoma cells may have stopped producing antibody which
could explain the low number of PFC obtained with this plaque assay. The
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Table 6
Effect of serial dilutions of anti-Ig antiserum (As)
on the number and size of plaques formed
(slide method #2)
Dilution of As" Degree of Lvsis'' Plaque Size"
0 ++ 0.1-0.2 mm
1/200 +
1/800 +
1/1600 +
1/3200 +
1/6400 +
1/12800 + 0.1-0.2 mm
1/25600 ++ 0.1-0.3 mm
1/51200 ++ 0.1-0.3 mm
1 102400 ++ 0.2-0.4 mm
1 204800 ++(+) 0.2-0.4 mm
1 409600 +++ confluent
1 819200 +++ confluent
1 1638400 ++(+) 0.2-0.4 mm
1 3246800 + 0.1-0.2 mm
a antiserum used was rabbit anti-mouse IgG, IgA, IgM
(H+L) .
b Nfld.M2 hybrid oma cells were used at a concentration
of 5 x 103 cells per chamber of a slide .
++++ approx . 95-100% target cell lysis
+++( +) approx . 85-90% targ et cell lysis
+++ approx. 75-80% target cell lysis
++(+) approx . 60-70% targ et cell lysis
++ approx. 50-55% target cell lysis
+( +) appr ox. 35-45% targ et cell lysis
+ approx. 20-30% targ et cell lysis
(+) approx. 10-15% target cell lysis
less than 10% target cell lysis
C some plaque sizes are not given becau se either there
were no plaques present or th ey were confluent .
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decline or loss of antibody production by hybridoma cells with time has been
reported before (Eshhar, Z., 1985). It was felt that recloning Nfld.M2 hybrids
might increase the number of PFC and hence increase the number of plaques.
The hybrids were therefore cloned out at as described in materials and
methods, section 2.11. After recloning , 14 out of the 60 wells plated at 1 and
0.5 cell/well achieved 50% confluency and the supernatants from thes e wells
were tested on CDC. Out of these 14 wells, 13 were positive and one was
negative for specific antibody production. Three of the wells that were very
strongly positive were grown up separately for testing in the plaque assay . For
clone 1, the plaque assay (slide method #2) was performed twice a week for
the first month and then once everyone or two weeks for another month. For
clones 2 and 3, the plaque assay was done less often . The slides were set up
with target cells (C.R.M.), hybridoma cells ranging from 6.2 x 102 to 1 X 104
per chamber and PI. Complement was added after incubation.
The results for clones 1, 2 and 3 are summarized in figures lla, b, and c,
respe ctively. The graphs show the average number of plaques per 5000 hybri-
doma cells versus the number of days. Day 0 represents the day Nfld.M2
clones were first set up on the plaque assay , two weeks after cloning . On that
day, the earlier (not recloned) culture of Nfld.M2 hybrids was also set up in
parallel with the cloned cells and the average plaques/5000 cells was deter-
mined to be 72 for the earlier culture. From the graphs, it can be seen that at
no time were there greater than 1111 PFC found per 5000 hybridoma cells
Figures lla, b, c: Change with time after cloning in percent of hybri-
doma cells secreting antibody (slide method #2).
Three separate graphs , for three clones of Nfld.M2 hybridorna cells, were plot-
ted to show the average plaques produced per 5000 hybridorna cells versus
days.
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plated; there was a remarkable variability in the number of PFC for all thre e
clones eac time they were set up ; a sharp drop in the number of PF C was
observed for each clone at day 3; there was a peak response (22%) at approxi-
mately two weeks and then gradually a drop in the number of PFC (0.5%)
with time. Since each clone came from 0.5-1 cell/well and cell growth was
obtained in only 14 out of the 60 wells, it is fair to conclude that at least one
of these was a clone. As they behaved similarly, probably all three were
clones. It is clear that antibody secretion, at a level detectable by this assay ,
occurs only in a small minority of cells in a clone, at anyone time. Thi s
interesting and unexpected finding is dealt with in more detail in the 'discus-
sion ' sect ion.
3.5.2. Experiments with hybridoma cells from Nftd.Ml cultures
Nfld.Ml is a non-cytotoxic antibody of IgGI subclass with anti-DR4
specificity (materials and methods, section 2.3.IA). It had previously been
clone twice . The following experiments were set up to see if Nfld.Ml antibody
could be used in a complement dependent lysis method by the addition of an
anti-Ig antiserum (rabbit anti-mouse IgG , 19A and IgM). T.P. cell line cells
(DR2,4 , see table 1) were used as a source of target cells. These experim ents
were set up twice using both slide methods #1 and #2. In method #1, the
slides were set up with Nfld .Ml hybridoma cells at a concentration of 1 x 106
per chamber, together with target cells, serial dilutions of antiserum ranging
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from 1/2 to 1/81g2, PI and complement. In method #2, slides were set up
with target cells, Nfld.Ml hybridoma cells at a concentration of 1 x 106 per
chamber and PI. After incubation , serial dilutions of antis erum ranging from
1/2 to approximately 1/1 x 106 were ad ded to t he slides. Compl ement was
added after another incubation. No effect of antiserum was observed in either
method and these slides were found to be no different from th e ones that con-
tained hybridoma cells but no antiserum. Approximately 20% cell lysis was
seen in all these slides whereas in the slides without hybridoma cells, only 5%
lysis was seen . Thus, contrary to expectation , Nfld .Ml could not be used in
this plaque assay even with the addition of a second developing antibody.
3.5.3. Experiments with supernatant from Nfld.Hl cultures on vari-
ous target cells
All the experiments described abov e involv ed the use of mouse hybridoma
cells. The following experiments were done using human hybridoma cells,
referred to as Nfld.H1 (materials and methods , section 2.3.1B) in order to see if
this plaque assay could be used in a human hybridoma system. Nfld.H1 anti-
body is an IgM and is known to be cytotoxic in CDC, when used undiluted ,
although it has variable reactivity depending on the target cell line used. It is
known to be most positive on DR2 and DQw1 positiv e cell lines. In two
separate experiments , slides were set up with undiluted supernatant from an
overgrown culture of Nfld.H1 which had been cloned twice, along with various
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target cells of different HLA phenotypes (table 1) and PI. Complement was
added after incubation. No lysis was seen at all for any of the target cells.
The supernatant was then concentrated 50-fold and set up again. The results
are shown in table 7. E.A. , K.H. and B.C. were negative with Nfld.Hl and th e
rest of the cell lines reacted with it to vary ing degrees. The reactions did not
correlate well with the DR and DQ specificity of the cells.
Experiments with Nfld.Hl hybridoma cells were also done to see if plaques
could be produced. In two separate experiments, target cells (C.H.M.), hybri-
doma cells at a concentration of 1 x 106 per chamber and PI were set up on
slides and incubated. Complement was then added and the slides were dried
and examined. The negative control gave 5% lysis. The slides with hybri-
doma cells gave approximately 15-20% lysis but no definite plaques. Experi-
ments with lower concentrations of hybridoma cells also did not produce any
plaques.
3.6.4. Experiments with EBV-transformed cells as Ase
B cells from a male volunteer (W.H.M.) who had been immunized with
peripheral blood lymphocytes (PBLs) from another male volunteer (C.H.M.)
were isolated at various intervals after immunization and transformed with
EBV (materials and methods , section 2.3.1B). These EBV-transformed cells
were used in the plaque assay as a source of ASC. The ultimate aim of th is
experiment was to determine the frequency of specific antibody-forming cells in
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Table 7
Degree of lysis of various target cells when tested
with concentrated (50-fold) Nfld.Hl antibody
(slide method #2)
Target Cell Line DR DQ Degree of Lysis»
E.A . 2,3 wI
B.C. 4,5 w3,w3
D.C. 2,?w6 wI ++(+)
E.C . 2 wl,- +++
M.C. 2,3 wl ,w3 ++
K.H. 3,4 w2,w3
C.A.K. 2,5 wl,w3 ++
C.H.M. 1,3 wl ,w2 ++
L.R . 2,w9 wI +
GM3161 22 wI ++
*++++
+++(+)
+++
++(+)
++
+(+)
+
(+)
approx . 95-100% target cell lysis
approx . 85-90% target cell lysis
approx . 75-80% target cell lysis
approx . 60-70% target cell lysis
approx . 50-55% target cell lysis
approx . 35-45% target cell lysis
approx. 20-30% target cell lysis
approx. 10-15% target cell lysis
less than 10% target cell lysis
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the blood and to determine the time of the peak response . An immediate
objective was to see if this plaque assay could be used for this type of human
ASC. These are results from four separate time points (i)-(iv) and they are
summarized in table 8.
(i) Cells from four culture tubes containing cells isolated 11 days post-
immunization were set up on the plaque assay. These cells had been in culture
for 8 days and a differential count revealed approximately 3 x 105 cells/tube of
which approximately 10-20% were blasts. One slide was set up per tube along
with target cells (C.H.M.) and PI. Complement was added after incubation.
Out of these four slides, three did not contain any plaques and one contained
15 plaques. These plaques were quite clear and distinct and ranged in size
from 0.1 to 0.2 mm.
(ii) Cells from one culture tube containing B cells isolated 14 days post-
immunization were set up on the plaque assay. They had been in culture for 5
days and a differential count revealed approximately 3 x 105 cells/tube of
which approximately 5% were blasts. No plaques were found.
(iii) Cells from four culture tubes containing B cells isolated 19 days post-
immunization were set up on the plaque assay. They were set up 9 (1 tube),
11 (1 tube), and 14 (1 tube with EBV and one without EBV) days after cultur-
ing. None, 2, 8, 1 plaques were found , respectively . The plaques ranged from
0.1-0.2 mm in size.
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Table 8
Number of plaques formed with human PBLs
collected and transformed with EBV at
various days post-immunization
Tube # Days Number of Plaques''Post-Immunizationa In Culture
1 11 8 0
2 11 8 0
3 11 8 0
4 11 8 15
5 14 5 0
6 19 9 0
7 19 11 2
8 19 14 8
9 19 14 (no EBV) 1
10 22 8 0
11 22 11 0
a represents days from immunization to blood collected.
b plaques ranged from 0.1-0.2 mm in diameter.
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(iv) Cells from two culture tubes containing B cells isolated 22 days
post-immunization were set up on the plaque assay . Th ey had been in culture
8 and 11 days. No plaques were found .
In conclusion, EBV-transforme d cells can be used in the plaque assay as a
source of ASC . The plaques formed are clear and distinct although smaller
than the ones found for mouse hybridoma cells. This may probably be due to
lower an tibo dy secretion by the EBV-transformed cells as compared to the
mouse hybridoma cells. From the above experiments , it is not possible to
establish t he time of the peak response .
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CHAPTER 4
DISCUSSION
4.1. Specificity of the plaque assay
The specificity of the plaque assay was clearly demonstrated by the fact
that when various target cells of different phenotypes were incubated with
Nfld.M2 antibody which is anti-lILA-A2 and A28, lysis was observed only in
the cells that expressed A2 and/or A28. No lysis was seen when cells express-
ing an unrelated antigen were used as targets (results, section 3.3.6). The fact
that Nfld.M2 antibody which is of IgG2a subclass causes lysis of nucleated tar-
get cells shows that the density of the epitopes, in this case on lILA class 1
molecules, is high enough on the target cell membrane for the IgG molecules
which bind to them to activate the complement system. This contrasts with
the antigens present on the surface of sheep erythrocytes since they are often
unable to combine with IgG in a way that triggers the complement cascade.
The latter antibodies usually need to be revealed by the addition of anti-IgG
antibody to the preparation (Sterzl and Riha, 1965; Dresser and Wortis, 1965).
The plaques obtained were usually clear and distinct with diameters rang-
ing from 0.1-0.4 mm. Fuji, Zaleski and Milgrom (1971), using thymus cells as
targets reported plaque diameters of 0.1-0.8 mm. Taylor and Bennett (1973),
using tumor (lymphoma) cells as targets, obtained plaque diameters ranging
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from 0.1-0.2 mm. When RBC were used as targets, plaque diameters ranging
from 0.1-1.0 mm were obtained (Jerne, Henry, Nordin, Fuji, Koros and Lefko-
vits,lQ74).
The variation in plaque size, when a hybridoma producing a monoclonal
antibody is used, could be due to the rate of antibody secretion by the plaque-
forming cell (PFC) and the rate of diffusion of these molecules from the PFC
to the target cells (Bussard, 1QgO). Other factors that affect plaque size in a
more heterogeneous population of ASC is epitope density, and the affinity and
avidity of the antibody secreted (Jerne, Henry, Nordin, Fuji, Koros and Lefko-
vits, 1Q74, Bussard, 1QgO).
Variation in plaque size can also be due to the type of cells used as targets
and their susceptibility to complement-mediated lysis. RBC are found to be
more susceptible to lysis by complement because the formation of a single
complement channel per cell is sufficient to cause lysis, whereas, with
nucleated cells, several complement channels are required for lysis (Koski,
Ramm, Hammer, Mayer and Shin, 1Qg3). This is because the rate of channel
elimination by the nucleated cells is high, whereas, for erythrocytes, it is nil.
Also, nucleated cells have effective membrane-associated ion pumps which
counteract the disturbance of osmotic balance that occurs when there is an ion
flux through the complement channels. Lastly, the osmotic fragility of
nucleated cells is lower than that of RBC (Ramm, Whitlow and Mayer, 1Qg4).
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4.2. Comparison of slide method #1 with method #2
Slide method #2 was found to be more sensitive than slide method #1 in
detecting plaques. When the two methods were set up in parallel and incu-
bated for the same length of time, the ratio of PFC for slide method # 1 as
compared to slide method #2 was approximately 1:7 (results, section 3.4.3).
This difference may be due to the fact that in slide method #2, complement
was present in excess whereas in slide method #1, a limited volume of comple-
ment was added. Also, since for slide method #1, complement is present right
from the start it may perhaps be uselessly consumed. Alternatively, the rabbit
serum which is used as a complement source may act as an inhibitor of suc-
cessful antibody secretion in some way. This theory can be tested by setting
up method #2 with complement present both from the beginning and added
later.
4.3. Percentage of Nfld.M2 hybridoma cells forming
plaques
In slide method #1, less than 5% of Nfld.M2 hybridoma cells that were
plated were found to be forming plaques (results, section 3.3.g). This percen-
tage of PFC was increased (22%) in slide method #2 since it was found to be
more sensitive than slide method #1, and also the Nfld.M2 hybridoma cells
had been recently cloned. The finding that only a small proportion of hybri-
doma cells, in a cloned culture, were actually secreting complement fixing anti-
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body, at anyone time, was unexpected. The possibility that the experimental
manipulations, especially exposing the hybrids to 45 0 C, might be altering the
viability and/or func tion of the hybrids was considered but later ruled out
when repeated trials, with varia tions in the temperature and the time of expo-
sure to the raised temperature, showed no consistent effect (results, section
3.3.9A & B). Following is a review of some of the results obtained by other
investigators using various hybridomas and myelomas to produce specific
plaques .
Bussard (1980) used a hybridoma resulting from a fusion between immune
spleen cells and a myeloma . It produced an anti-SRBC antibody of IgM class.
He found that the number of cells that formed plaques in a direct hemolytic
plaque assay depended on the 'period of growth at which they were collected '.
If the hybridoma cells were taken at the beginning of the exponential growth,
10-15% formed plaques whereas if they were taken the end of the exponential
growth , 65-70% formed plaques. He concluded that this must reflect the
operation of a regulatory mechanism in vitro.
Rector , Lang, Carter, Kelly , Bundesen , BOttcher and Sehon (1980) used
hybridornas resulting from the fusion between immune spleen cells and P3X20
myeloma cells. They obtained approximately 30% PFC with both IgE and
IgGl-secreting hybridornas using the reverse hemolytic plaque assay (RHPA ;
introdu ction , sect ion 1.3); and 31% PFC using a hybridoma secreting an anti-
SRBC antibody of IgM class in a direct hemolytic plaque assay. They agreed
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with the findings of Bussard (1980) and concluded that the majority of the
cells maintained in non-synchronized cultures were in a non-secreting phase of
their cycle when tested .
Moller and Borrebaeck (1985), used a hybridoma (ID5-8B) that resulted
from a fusion between immune spleen cells and SP2/0-AgI4 plasmacytoma. It
was cloned three times before it was used in the filter immuno-plaque assay
(FIPA; introduction, section 1.4). In their assay, approximately 5% of the cells
were found to be producing plaques.
When myeloma cells were used as a source of antibody-secreting cells
(ASC), 10-70% (Gronowicz, Coutinho and Melchers, 1976; RHPA), 10-15%
(Rector, Carter, Kelly, Lang and Sehon, 1979; RHPA) , and 32-39% (Holt,
Cameron, Stewart, Sedgwick and Turner, 1984; ELISA-plaque assay; introduc-
tion, section 1.4) were found to be producing plaques. It was concluded that
the non-plaque-forming fraction of the cells could be either precursors not yet
capable of secreting or end cells that had lost the capacity to secrete, or else
cells in the non-secreting phase of their cell cycle.
From the evidence so far, the low percentage of PFC observed in hybri-
doma cell cultures is attributed to the fact that, in non-synchronized cultures,
the majority of the cells are in a non-secreting phase of their cell cycle.
Whether this is the case with NOd.M2 hybridoma cells can be tested by syn-
chronizing the cell cultures and then testing the cells in a plaque assay over a
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period of time. Some of the findings in this lab, using human hybridoma cells
as a source of ASC in a RHPA, have suggested that nutrition may be involved
in reducing the number of PFC. There may be a deficiency of growth factors,
for example, B cell differentiation factor, which is known to induce antibody
production by B cells, (Muraguchi, Kehrl, Butler and Fauci, H)84), or of some
essential nutrients, such as a particular amino acid that may be required by
the cells for antibody production. Carefully controlled experiments, in terms
of culture conditions, nutrients and growth factors are required to determine
the effect of these on the number of PFC .
4.4. Effect of anti-immunoglobulin antiserum
The prozone effect observed for slide method #1 was thought to occur
because the antiserum was present right from the time when the slides were
first set up (results, section 3.3.10). It was thought that the anti-Ig formed
complexes with the secreted antibody and thus affected its ability to diffuse
through the agar and bind to the target cells. For this reason, slide method
#2 was developed in which the surface of the agar was exposed so that the
antiserum could be added after the initial incubation with the ASC. The same
prozone effect was observed again, although the optimal concentration of
antiserum required to increase target cell lysis was considerably lower (1/400-
1/800 for slide method #1; 1/40g,600-1/81g,200 for slide method #2). The
fact that the antiserum needed to be diluted more for slide method #2 in
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order to see the enhancing effect could be due to differences in the volume of
antiserum added, since only 5 pI of antiserum was added to the slides in slide
method #1, whereas, in slide method #2, the slides were flooded with
antiserum. The fact that the same prozone effect was also observed for slide
method #2 inval idates the argument presented for slide method #1 that it
was due to the antiserum being present right from the beginning.
The inhibition in plaque formation observed for both methods at high
concentrations of antiserum was similar to that observed by Sterzl and Riha
(1965) and Dresser and Wortis (1965). They found that an optimal concentra-
tion of antiserum was required for maximal development of plaques and that
higher concentrations resulted in inhibition. Gronowicz, Coutinho and Melch-
ers (1976), using the RHPA, also reported that plaque formation was highly
dependent on the concentration of developing antibody. They showed that too
low or too high a concentration of antiserum resulted in inhibition of plaque
formation.
The increase in target cell lysis (plaque diameter) due to a secondary anti-
body at high hybridoma cell concentrations, which was found for both
methods, is puzzling. One possible explanation could be that as the hybri-
doma cells secrete their antibody, it diffuses through and coats peripheral tar-
get cells with sublytic doses of antibody. Since the concentration of hybri-
doma cells is high, and consequently the distance between two PFC is low,
there may be a certain amount of overlapping, i.e. peripheral target cells may
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be being coated with antibody from more than one PFC. Such a sublytic dose
may not be enough to activate the complement or alternatively, it is known
that even if the complement system is activated, it may not be enough to
cause lysis, since lysis of nucleated mammalian cells by complement requires
formation of several channels per cell (Koski, Ramm, Hammer, Mayer, and
Shin, 1983). The addition of antiserum may result in enough Fe regions being
exposed, that complement activation results in target cell lysis, which may
result in bigger plaques (confluent plaques).
At low hybridoma cell concentrations, the increase in target cell lysis by
the addition of optimal dilutions of antiserum is not seen. This may be due to
the fact that the distance between two PFC is large and thus there is no over-
lapping, i.e. the peripheral target cells are just coated with sublytic doses of
antibody from one PFC and this may not be enough to react with antiserum
and cause target cell lysis. This interpretation suggests the possibility of using
a second antibody in the agar at sub lytic concentrations, to increase the sensi-
tivity of the plaque method, at least in terms of plaque size, if not of plaque
number.
4.5. Cloning
Nfld.M2 hybridoma cells were cloned and the number of PFC was fol-
lowed over a period of time (results, section 3.5.1). The number of PFC after
cloning increased from 72 per 5000 cells plated for the earlier (not recloned)
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cells to 5g4, 680 and 441 for clones 1, 2, and 3, respectively. There was a
sharp peak response for all three clones at approximately 2 weeks of testing.
The maximum number of PFC observed was for clone 1 at two weeks (1111
out of 5000 cells plated; results , figure 11a). Alter the peak, there was a gra-
dual decline in antibody production till after two months, approximately 0.5%
of the cells were making plaques.
This drop in PFC cannot by explained by mutation, or loss of chromo-
somes, since such changes are irreversible and this does not seem to be the case
with these hybridoma cells for the following reasons . First, it was found that
when these cells were cloned out at 0.5-1 cell/well , more than gO% of the wells
tested were positive for specific antibody. Second, the number of cells secret-
ing an tibody varied from day to day. Again , as in section 4.3, this low number
of PFC (22%) , which dropped to an even lower number (0.5%) may be due to
lack of nutrition, perhaps some factor that is limiting in the cell culture.
Alternatively, the majority of the cells may be in a non-secreting phase of their
cell cycle, or both. The first hypothesis can be tested by adding growth fac-
tor s, known amounts of different amino acids and other nutrients to the cell
cultures to see if these have an effect on the number of PFC. The second
hypothesis can be tested, as mentioned before , by synchronizing the cell cul-
ture and then testing the hybridoma cells in a plaque assay over a period of
time .
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4.6 Nfld.Ml
Nfld.Ml produces a non-complement fixing antibody of IgGl subclass and
anti-DR4 specificity. Efforts to induce target cell lysis or plaque formation
with Nfld.Ml by the addition of antiserum were unsuccessful, for both slide
methods #1 and #2 (results, section 3.5.2). Plaques observed by other investi-
gators, using nucleated cells as targets, have been IgM plaques. Nordin, Cerot-
tini and Brunner (1971) were unable to demonstrate IgG plaques by the use of
specific antisera to each of the IgG subclasses. The reason why the addition of
antiserum does not induce the activation of complement when nucleated cells
are used as targets as it does when erythrocytes are used, is puzzling. Perhaps,
the Ig-anti Ig complex formed on the surface of the nucleated cells gets capped
and internalized. This is common with nucleated cells but not with erythro-
cytes. Alternatively, the Ig-anti-Ig complex may be activating the comple-
ment, but this may not be sufficient to cause target cell lysis. If the epitope
density on lILA class II molecules is low, then even with the addition of
antiserum, not enough complement channels may be forming to cause lysis of
the target cells as it would with erythrocytes.
The latter hypothesis can be tested by treating the target cells with puro-
mycin. Puromycin inhibits protein synthesis and it has been shown to increase
the osmotic fragility of nucleated cells; to reduce the rate of ion pumping; to
reduce the rate of membrane repair by affecting the synthetic capability of the
cell; and to reduce the rate of channel elimination (Ramm, Whitlow and
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Mayer, 1984). All these factors combine to make the cells more susceptible to
lysis. Therefore, the target cells can first be treated with puromycin and then
set up on a plaque assay with Nfld.Ml to see if plaques can be observed by the
addition of antiserum.
4.7. Nfld.Hl
Nfld.Hl is an IgM producing human-human hybridoma. It was of interest
to see if plaques could be produced with these hybrids since the secreted anti-
body has been shown to be cytotoxic. Neither plaques nor target cell lysis was
observed when Nfld.Hl hybridoma cells were set up on the plaque assay. This
was perhaps not surprising since the supernatant from an overgrown culture of
Nfld.Hl had to be concentrated SO-fold before any target cell lysis was
observed. Human hybridomas are known to secrete low amounts of antibody
as compared to mouse hybridomas. Incubation of the slides for up to 6 hours
(2 hour incubations are normally performed) with the hybridoma cells did not
have any effect (data not given). Incubations longer than 6 hours resulted in
non-specific target cell death as well as fading of the fluorescence. Therefore,
whether longer incubations result in enough antibody production to cause tar-
get cell lysis could not be determined. Nordin, Cerottini and Brunner (1971),
using spleen cells from immunized mice and nucleated target cells found
plaques after 24 hours incubation. Such long incubations could not be per-
formed for this method as the fluorescence tended to fade and leak out of the
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target cells 10-12 hours after labelling.
4.8. EBV-transformed cells
Plaques were obtained when EBV-transformed human cells were used as
ASC. The plaques were smaller than the ones obtained with mouse hybridoma
cells, probably due to lower antibody secretion, but they were clear and dis-
tinct. The successful adaptation of this plaque method for use with human
cells should be valuable to people attempting to produce human monoclonal
antibodies since it will illuminate events in a cell culture at the most revealing
level, that of the single cell.
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